0001213900-14-007089.txt : 20141003 0001213900-14-007089.hdr.sgml : 20141003 20141003151332 ACCESSION NUMBER: 0001213900-14-007089 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20141003 DATE AS OF CHANGE: 20141003 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-39976 FILM NUMBER: 141139541 BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE C-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE C-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Hy Biopharma Inc CENTRAL INDEX KEY: 0001407227 IRS NUMBER: 235067192 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 2500 YORK ROAD STREET 2: SUITE 100 CITY: JAMISON STATE: PA ZIP: 18929 BUSINESS PHONE: 215-918-3336 MAIL ADDRESS: STREET 1: 2500 YORK ROAD STREET 2: SUITE 100 CITY: JAMISON STATE: PA ZIP: 18929 SC 13G 1 sc13g0914hybio_soligenix.htm SCHEDULE 13G

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. ___)*

 

Soligenix, Inc.

 

(Name of Issuer)

Common Stock, $0.001 par value per share

 

(Title of Class of Securities)

258094101

 

(CUSIP Number)

September 3, 2014

 

(Date of Event Which Require Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

☐ Rule 13d-1(b) (Qualified Investor)

☒ Rule 13d-1(c) (Passive Investor)

☐ Rule 13d-1(d) (Exempt Investor)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (as amended, the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No. 258094101

 

1

NAMES OF REPORTING PERSONS.

Hy BioPharma, Inc.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) 

(b) 

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

SOLE VOTING POWER

1,608,354

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

1,608,354

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,608,354

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)



11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)**

7.3%

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

       

Page 2 of 4 pages
 

 

Item 1(a). Name of issuer:

Soligenix, Inc.

Item 1(b). Address of issuer's Principal Executive Offices:

29 Emmons Drive,

Suite C-10

Princeton, NJ 08540

 

Item 2(a). Name of person filing:

Hy BioPharma, Inc.

 

Item 2(b). Address of principal business office or, if none, Residence:

2500 York Road, #100

Jamison, PA 18929

 

Item 2(c). Citizenship:

See Item 4 of the cover page.

Item 2(d). Title of class of securities:

Common Stock, $0.001 par value per share.

Item 2(e). CUSIP No.:

258094101

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not Applicable.

Item 4.  Ownership.

 

See Items 5-9 of the cover page.

Item 5. Ownership of 5 percent or less of a class:

Not Applicable.

Item 6. Ownership of more than 5 percent on behalf of another person:

Not Applicable.

Item 7. Identification and classification of subsidiary which acquired the security being reported on by the parent holding company or control person:

Not Applicable.

Page 3 of 4 pages
 

 

Item 8. Identification and classification of members of the group:

Not Applicable.

Item 9. Notice of dissolution of the group:

Not Applicable.

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 24, 2014 HY BIOPHARMA, INC.
     
  By: /s/ Robert J. Capetola
  Name: Robert J. Capetola
  Title: Chief Executive Officer

 

 

Page 4 of 4 pages